HRSV (B) Post-fusion glycoprotein F0, His Tag (MALS verified)

Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, single-chain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable post-fusion conformation.

This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 55.2 kDa. The protein migrates as 16-18 kDa and 43-50 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

-20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Immobilized HRSV (B) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H9) at 1 μg/mL (100 μL/well) can bind Anti-Fusion glycoprotein F0 Antibody, Mouse IgG2a (101F) with a linear range of 0.1-4 ng/mL and not bind Anti-Fusion glycoprotein F0 Antibody, Human IgG1 (D25) (QC tested).